✨ Free AI Report
Galmed Pharmaceuticals Ltd.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Galmed Pharmaceuticals Ltd.
Research Preview

Galmed Pharmaceuticals Ltd.: Business Overview, Financials & Competitive Analysis

Galmed is a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, and gastrointestinal oncology indications. Its flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conj...

Analyst-debate audio for Galmed Pharmaceuticals Ltd.

AskCyborg analysts argue the bull and bear cases for Galmed Pharmaceuticals Ltd. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Galmed Pharmaceuticals Ltd. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
5/ 10Mixed

Cyborg Score thesis

Small-cap biotech with differentiated NASH asset and expansion potential, but clinical validation and partnership execution...

Read the full analyst-debate transcript →
Industry Biopharmaceutical / Drug Development
2 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: June 22, 2026
AI-Verified Research
30+ Page Report

Get the Latest Galmed Pharmaceuticals Ltd. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Galmed Pharmaceuticals Ltd. Overview

Pro stress-test →

Galmed is a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, and gastrointestinal oncology indications. Its flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule currently in Phase III development for NASH/MASH treatment.

Strategic Profile

Pro stress-test →

Galmed has discovered a proprietary pharmacodynamic blood-based biomarker signature for Aramchol, positioning the company for expansion beyond liver disease. With a new patent, Galmed extended Aramchol's patent protection through September 2039, securing a 15-year exclusivity runway. The company is pursuing oncology partnerships and combination therapy strategies.

Competitive Landscape

Pro stress-test →

Galmed focuses on liver, cardiometabolic, and GI oncology indications in a competitive NASH/MASH market dominated by larger players. The company differentiation relies on Aramchol's first-in-class status and recently validated biomarker signature. Competitors include Madrigal (Rezdiffra) and other metabolic disease developers, though Galmed emphasizes combination therapy and multi-indication expansion as competitive advantages.

Industry Context

Galmed Pharmaceuticals Ltd. operates in Biopharmaceutical / Drug Development.

Key facts

Founded: 2000 · Headquarters: Ramat Gan, Israel · Employees: 6 employees as of January 26, 2026

What the analysts stress-tested

The top findings that survived the multi-agent debate for Galmed Pharmaceuticals Ltd..

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Galmed Pharmaceuticals Ltd. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

RezdiffraNASH/MASH therapy with complementary mechanism to Aramchol→StivargaGI cancer standard-of-care drug being combined with Aramchol in planned trials→

Compare Galmed Pharmaceuticals Ltd. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Galmed Pharmaceuticals Ltd. operates in Biopharmaceutical / Drug Development. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical / Drug Development research →
NEW · MCP server

Ask your AI assistant about Galmed Pharmaceuticals Ltd.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Galmed Pharmaceuticals Ltd. and its top competitor on Cyborg Score”
“What did Galmed Pharmaceuticals Ltd. do this quarter?”
“Is Galmed Pharmaceuticals Ltd. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Galmed Pharmaceuticals Ltd. do?+
Galmed is a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, and gastrointestinal oncology indications. Its flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conj...
What is Galmed Pharmaceuticals Ltd.'s Cyborg Score?+
Galmed Pharmaceuticals Ltd. has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Galmed Pharmaceuticals Ltd.'s main competitors?+
Named competitors include Rezdiffra, Stivarga. The full competitive landscape is in the AskCyborg report.
How can I get the full Galmed Pharmaceuticals Ltd. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Galmed Pharmaceuticals Ltd. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Galmed Pharmaceuticals Ltd. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

Other strong performers across the analyst-debate framework. Click any to see their research report.

9Phnom Penh Water Supply Authority9ESCO Technologies Inc.9Evolution Mining Limited9CoreWeave, Inc.9Nintendo Co., Ltd.9Waste Management, Inc.9CrowdStrike Holdings, Inc.9SK Hynix Inc.9Kweichow Moutai Co., Ltd.9Apple Inc.8Domino's Pizza, Inc.8Pro-Dex, Inc.8Palladyne AI Corp.8Mo-BRUK S.A.8Kuwait Reinsurance Company K.S.C.P.8Red River Bancshares, Inc.8PTC India Limited8IsoEnergy Ltd.